Strong augment effect of IL-12 expression plasmid on the induction of HIV-specific cytotoxic T lymphocyte activity by a peptide vaccine candidate

Clinical Immunology and Immunopathology

Volumn 83, Issue 2, 1997, Pages 179-184

  Hamajima, Kenji ^a   Fukushima, Jun ^a   Bukawa, Hiroki ^a   Kaneko, Tamiko ^a   Tsuji, Takashi ^a   Asakura, Yuusuke ^a   Sasaki, Shin ^a   Xin, Ke Qin ^a   Okuda, Kenji ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SPLEEN CELL; VIRUS INACTIVATION;

EID: 0031002276     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1997.4348     Document Type: Article

References (42)

1. Goudsmit J. Human immuunodeficiency virus type 1 neutralization epitope with conserved architecture elicite early type-specific antibodies in experimentary infected chimpanzees. Proc. Natl. Acad. Sci. USA. 85:1987;4478-4482.
2. Ho D. D., Kaplan J. C. Second conserved domain of gp 120 is important for HIV infectivity and antibody neutralization. Science. 239:1988;1021-1023.
3. Achour A., Picard O., Zagury D., Sarin P. S., Gallo R. C., Naylor P. H., Goldstein A. L. HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc. Natl. Acad. Sci. USA. 87:1990;7045-7049.
4. Staats H. F., Nicols W. G., Palker T. J. Mucosal immunity to HIV. Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J. Immunol. 156:1966;462-471.
5. Bukawa H., Sekigawa K-I., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV-1 secretory Ig A induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Med. 1:1996;681-685.
6. Charbit A., Marineau P., Ronce J., Leclerc C., Lo-Man R., Michel V., O'Callaghan, Hofnung M. Expression and immunogenicity of the V3 loop from the envelope of human immunodeficiency virus type 1 in attenuatedaroASalmonella typhimuriumEscherichia coli. Vaccine. 11:1993;1221-1228.
7. Natuk R. J., Lubeck M. D., Chanda P. K., Chengalvala M., Wade M. S., Murthy S. C. S., Wilhelm J., Vernon S. K., Dheer S. K., Mizutani S., Lee S. G., Murthy K. K., Eichberg J. W., Davis A. R., Hung P. P. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res. Hum. Retroviruses. 9:1993;395-404.
8. Johnson P. P., Hammond S. A., Trocha A., Siliciano R. F., Walker B. D. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine. J. Virol. 68:1994;3145-3153.
9. Fuller D. H., Haynes J. R. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses. 11:1994;1433-1442.
10. Okuda K., Bukawa H., Hamajima K., Kawamoto S., Sekigawa K., Yamada Y., Tanaka S., Ishii N., Aoki I., Nakamura M., Yamamoto H., Cullen B. R., Fukushima J. Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the type 1envrev. AIDS Res. Hum. Retroviruses. 11:1995;933-943.
11. Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chang S., Loudon R., Sherman F., Perussia B., Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a factor with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:1989;827-845.
12. Stern A. S., Podlaski F. J., Hulmes J. D., Pan Y. C. E., Quinn P. M., Wolitzky A. G., Familletti P. C., Stremlo D. L., Truitt T., Chizzonite R., Gately M. K. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA. 87:1990;6808-6812.
13. Wolf S. F., Temple P. A., Kobayashi M., Young E., Dicig M., Lowe L., Dzialo R., Fitz L., Ferenz C., Hewick R. M., Kelleher K., Herrmann S. H., Clark S. C., Azzoni L., Chan S. H., Trinchieri G., Perussia B. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effect on T and natural killer cells. J. Immunol. 146:1991;3074-3081.
14. Gubler U., Chua A. O., Schoenhout D. S., Dwyer C. M., McComas W., Motyka R., Nabavi N., Wolitzky A. G., Quinn P. M., Familletti P. C., Gately M. K. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA. 88:1991;4143-4147.
15. Schoenhaut D. S., Chua A. O., Wolitzsky A. G., Quinn P. M., Dwyer C. M., McComas W., Familletti P. C., Gately M. K., Gubler U. Cloning and expression of murine IL-12. J. Immunol. 148:1992;3433-3440.
16. Chan S. H., Perussia B., Gupta J. W., Kobayashi M., Pospisil M., Young H. A., Wolf S. F., Young D., Clark S. C., Trinchieri G. Induction of Interferon-γ production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:1991;869-879.
17. Sypek J. P., Chung C. L., Mayor S. E. H., Subramanyam J. M., Goldman S. J., Sieburth D. S., Wolf S. F., Schaub R. G. Resolution of cutaneous Leishmaniases: Interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1993;1797-1802.
18. Heinzel F. P., Schoenhaut R., Rerko R. M., Roser L. E., Gately M. K. Recombinant interleukin 12 cures mice infected with Leishmania major. . J. Exp. Med. 177:1993;1505-1509.
19. Brunda M. J., Luistro L., Warrier R. R., Wright R. B., Hubbard B. R., Murphy, Wolf S. F., Gately M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tomors. J. Exp. Med. 178:1993;1223-1230.
20. Okuda K., Kaneko T., Yamakawa T., Tanaka S., Aoki I., Hamajima K., Kawamoto S. Strong synergistic effect of multicomponent vaccine for human immunodeficiency virus infection. J. Clin. Lab. Immunol. 40:1993;97-113.
21. Bukawa H., Fukushima J., Hamajima K., Kimura M., Tsuji T., Xin K.-O., Okuda K. Antibody responses rainsed against a conformational V3 loop peptide of HIV-1. Microbiol. Immunol. 39:1995;607-614.
22. Hamajima K., Bukawa H., Fukushima J., Kawamoto S., Kaneko T., Sekigawa K-I., Tanaka S-I., Tsukuda M., Okuda K. A macromolecular multicomponent peptide vaccine prepared using the glutaraldehyde conjugation with strong immunogenicity for HIV-1. Clin. Immunol. Immunopathol. 77:1995;374-379.
23. Inami S., Taniguchi N., Ishibashi K., Nagao T., Aoki I., Ishii N., Okuda K. Serum antibody directed against synthetic peptides derived from HIV-1 protein sequence obtained from 26 Japanese HIV-1 infected individuals. AIDS. 5:1991;1140-1141.
24. Okuda K., Bukawa H., Kawamoto S., Inami M., Saito T., Phanuphak P., Hamajima K. A serologic analysis and amino acid sequence of the V3 region of human immunodeficiency virus from carriers in Bangkok. J. Inf. Dis. 169:1994;227-228.
25. Ubolyam S., Ruxrungtham K., Sirivichayakul S., Okuda K., Phanuphak P. Evidence of three HIV-1 subtypes in subgroups of individuals in Thailand. Lancet. 344:1994;485-486.
26. Mckeating J. A., Cordell J., Dean C. J., Balfe P. Synergistic interaction between ligands to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology. 191:1992;732-742.
27. Kawamoto S., Uchino S., Hattori S., Hamajima K., Mishina M., Nakajima-Iijima S., Okuda K. Expression and characterization of the ζ1 subunit of the N-methyl-d-asparate (NMDA) receptor channel in a baculovirus system. Mol. Brain. Res. 30:1955;137-148.
28. Nehete P. N., Casement K. S., Arlinghaus R. B., Sastry K. J. Studies onin vivo. Cell. Immunol. 160:1995;217-223.
29. Niwa H., Yamamura K., Miyazaki J. Efficient selection for high-expression transfectants with a novel eukariotic vector. Gene. 108:1991;193-200.
30. Davis H. L., Kinder K., Zubler R. H. Semiquantitative, nonradioactive RT-PCR detection of immunoglobulin mRNA in human B cells. DNA Cell Biol. 13:1994;429-436.
31. +. Science. 234:1986;1563-1566.
32. Haynes B. F., Pantaleo G., Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:1996;324-328.
33. Miedema F., Klein M. R. AIDS pathogenesis: A finite immune response to blame? Science. 272:1996;505-506.
34. +. Nature. 44:1990;873-875.
35. Zheng B., Brett S. J., Tite J. P., Lifely M. R., Brodie T. A., Rhodes J. Galactose oxidation in the design of immunogenic vaccines. Science. 256:1992;1560-1563.
36. mac251gagenv. AIDS Res. Hum. Retroviruses. 10:1994;853-861.
37. Gupta R. K., Relyveld E. H., Lindblad E. B., Bizzini B., Ben-Efraim S., Gupta C. K. Adjuvant - A balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
38. Haddden J. W. T-cell adjuvants. Int. J. Immunopharmacol. 16:1994;703-710.
39. Golding B., Scott D. E. Vaccine strategies: Targeting helper T cell responses. Ann. NY Acad. Sci. 754:1995;126-137.
40. Gupta R. K., Siber G. R. Adjuvants for human vaccines - Current status, problems and future prospects. Vaccine. 13:1995;1263-1276.
41. Vogel F. R. The role of adjuvants in retroviral vaccines. Int. J. Immunopharmacol. 17:1995;85-90.
42. Xu-Amano B. J., Kiyono H., Jackson R. T., Staats H. F., Fujihashi K., Burrow P. D., Elson C. O., Pillai S., McGhee J. R. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvants selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 178:1993;1309-1320.